a three-arm head-to-head randomized clinical trial assessing two of the promising studied interventions, low-level diode laser and topical Chamomile, comparing them to each other's and to conventional therapy in the management of oral mucositis-induced chemotherapy.

The latest MASCC/ISOO Mucositis Guidelines recommend relieving pain, reducing inflammation, and preventing secondary infection as the main pillars in the management of chemotherapy-induced oral mucositis. Accordingly, our comparator will be conventional therapy, including topical anti-inflammatory, topical analgesic, and topical antifungal.

Inclusion criteria:

• Patients with chemotherapy-induced oral mucositis.
• Patients who will agree to participate in the study.
• Adult Patients above 18 years.

Exclusion criteria:

• Patients with any visible oral lesions other than oral mucositis.
• Patients who have received radiotherapy 2 weeks earlier to the diagnosis of the oral mucositis

Double-blinded trial:

The outcome assessor and the statistician will be blinded. Participants can't be blinded because of the difference in intervention methods of application.